Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Salehi M, Aulinger BA, DAlessio DA
2025;8:e2457349
In the ATTAIN-2 trial (participants with obesity and type 2 diabetes), GI adverse event rates were somewhat higher than in ATTAIN-1: nausea 20.1-36.4% versus 8.4% with placebo, vomiting 12.8-23.1% versus 3.8%, diarrhea 21.3-27.4% versus 15.0%, and constipation 17.7-22.4% versus 7.8%
Targeting mitochondrial complex I overcomes chemoresistance in high OXPHOS pancreatic cancer
Are sublingual tirzepatide drops effective
Deeply hydrates and enhances skin suppleness
US$ 23.45
US$ 29.84
US$ 27.54
US$ 27.02
